Simple Summary Advances in treatment, especially with novel drugs, have dramatically
improved the survival of multiple myeloma (MM) patients recently. However, frequent …

Nasopharyngeal carcinoma (NPC) represents a molecularly paradigmatic tumor given the
complex diversity of environmental as well as host dependent factors that are closely …

Anaemia is the most common complication of myeloma and is associated with worse clinical
outcomes. Although marrow replacement with myeloma cells is widely considered a …

Both the tumor and tumor microenvironment (TME) are crucial for pathogenesis and
chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM …

Gas-assisted therapy and diagnosis of tumors have attracted extensive interest due to their
low toxicity and convenience, but are severely limited by the uncontrollable gas release. In …

Multiple myeloma (MM) remains an incurable hematological malignancy. Bortezomib (BTZ)
is a proteasome inhibitor widely used in MM therapy whose potent activity is often hampered …

Despite several approved therapeutic modalities, multiple myeloma (MM) remains an
incurable blood malignancy and only a small fraction of patients achieves prolonged …

多发性骨髓瘤 (multiple myeloma, MM) 是一种高度异质性恶性浆细胞疾病. 蛋白酶体抑制剂
(proteasome inhibitors, PIs) 是治疗 MM 的一线药物, 硼替佐米, 伊莎佐米和卡非佐米也广泛 …

In the last 2 decades, we witnessed unprecedented progress in multiple myeloma research.
The median survival times doubled, and with the introduction of subsequent new …

多发性骨髓瘤(multiple myeloma， MM) 是一种高度异质性恶性浆细胞疾病。 蛋白酶体抑制剂(
proteasome inhibitors， PIs) 是治疗MM 的一线药物， 硼替佐米、 伊莎佐米和卡非佐米也广泛 …